Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy

Abstract The overall survival rates for lung cancer remain unsatisfactorily low, even for patients with biomarkers for which target therapies or immunotherapies are recommended. Better identification of at‐risk patients is needed to achieve more effective personalized treatment. Here, we derived a r...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chih‐Hsun Wu, Ming‐Jing Hwang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2019-10-01
coleção:	Cancer Medicine
Assuntos:	drug resistance gene signature lung cancer prognosis target therapy transcriptomics
Acesso em linha:	https://doi.org/10.1002/cam4.2492
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!